Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant neisseria meningitidis group B nadA protein adsorbed on aluminium hydroxide
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant Neisseria meningitidis group B NadA protein adsorbed on aluminium hydroxide is a specific antigenic component of the multicomponent meningococcal serogroup B vaccine, Bexsero (4CMenB). Developed by GSK (following the acquisition of Novartis Vaccines), this protein is a recombinant version of the Neisserial adhesin A (NadA), a surface-exposed trimeric autotransporter adhesin that plays a critical role in the adhesion and invasion of human epithelial cells by *Neisseria meningitidis*. In the vaccine formulation, the protein is adsorbed onto an aluminium hydroxide adjuvant to enhance its immunogenicity. Upon administration, it stimulates the production of specific bactericidal antibodies that target the NadA protein on the surface of the meningococcus, facilitating complement-mediated lysis and providing protection against invasive meningococcal disease caused by serogroup B strains.
- Brand names
- Bexsero
- Other names
- Neisserial adhesin ANadA proteinrecombinant Neisseria meningitidis group B NadA protein
02
Targets
NadA (Neisserial adhesin A)
Beyond the preview
Go deeper on recombinant neisseria meningitidis group B nadA protein adsorbed on aluminium hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant neisseria meningitidis group B nadA protein adsorbed on aluminium hydroxide.